×
About 434,046 results
Pelvic Organ Prolapse ACOG Practice Bulletin, Number 214
https://journals.lww.com/greenjournal/Abstract/2019/11000/Pelvic_Organ_Prolapse__ACOG_Practice_Bulletin,.44.aspx
Obstetrics & Gynecology;

Nov 29th, 2019 - Pelvic organ prolapse (POP) is a common, benign condition in women. For many women it can cause vaginal bulge and pressure, voiding dysfunction, defecatory dysfunction, and sexual dysfunction, which may adversely affect quality of life. Women in the United States have a 13% lifetime risk of undergoing surgery for POP (1). Although POP can occur in younger women, the peak incidence of POP sympto...

Update on the Management of Constipation
https://jamanetwork.com/journals/jama/article-abstract/2754106
JAMA Wald A

Nov 16th, 2019 - Chronic constipation is very common. The most recent estimate of clinician visits attributable to constipation were from 2001 to 2004 and reported more than 8 million clinician visits in the United States, with most occurring in adult primary care settings (33%) followed by pediatric (21%) and gastroenterologist (14%) offices.1 These encounters result in large expenditures for nonprescription l...

Depression in Children and Adolescents: Evaluation and Treatment
https://www.aafp.org/afp/2019/1115/p609.html
American Family Physician; Selph SS et al

Nov 16th, 2019 - he prevalence of major unipolar depression in children and adolescents is increasing in the United States. In 2016, approximately 5% of 12-year-olds and 17% of 17-year-olds reported experiencing a major depressive episode in the previous 12 months. Screening for depression in adolescents 12 years and older should be conducted annually using a validated instrument, such as the Patient Health Que...

FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma supported by clinical trial results showing high response rate of tumor shrinkage
https://www.fda.gov/news-events/press-announcements/fda-approves-therapy-treat-patients-relapsed-and-refractory-mantle-cell-lymphoma-supported-clinical
FDA

Nov 16th, 2019 - The U.S. Food and Drug Administration granted accelerated approval to Brukinsa (zanubrutinib) capsules for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.

2019 American Heart Association Focused Update on Advanced Cardiovascular Life Support: Use of Advanced Airways, Vasopressors, and Extracorporeal Cardiopulmonary Resuscitation During Cardiac Arrest...
https://www.ahajournals.org/doi/10.1161/CIR.0000000000000732
Circulation Panchal AR et al

Nov 16th, 2019 - The fundamentals of cardiac resuscitation include the immediate provision of high-quality cardiopulmonary resuscitation combined with rapid defibrillation (as appropriate). These mainstays of therapy set the groundwork for other possible interventions such as medications, advanced airways, extracorporeal cardiopulmonary resuscitation, and post–cardiac arrest care, including targeted temperature...

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
https://www.nejm.org/doi/full/10.1056/NEJMoa1912388?query=featured_home
New England Journal of Medicine; Tardif JC et al

Nov 16th, 2019 - Experimental and clinical evidence support the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis.

Snubbed by Scientists, Recognized 20 Years Later
https://www.medscape.com/viewarticle/920939
Medscape

Nov 16th, 2019 - When a team led by pathologist Robert Folberg, MD, noticed that uveal melanoma tumors seemed to organize themselves in packets, and between the packs were unexplained structures, the trajectory of their careers changed. The researchers found that some of the structures were solid and others were hollow, and the empty ones took the shape of channels containing red blood cells. At first, th...

FDA approves new antibacterial drug to treat complicated urinary tract infections as part of ongoing efforts to address antimicrobial resistance
https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibacterial-drug-treat-complicated-urinary-tract-infections-part-ongoing-efforts
FDA

Nov 16th, 2019 - The U.S. Food and Drug Administration today approved Fetroja (cefiderocol), an antibacterial drug for treatment of patients 18 years of age or older with complicated urinary tract infections (cUTI), including kidney infections caused by susceptible Gram-negative microorganisms, who have limited or no alternative treatment options.

Preexposure Prophylaxis for the Prevention of HIV Infection: Recommendation Statement
https://www.aafp.org/afp/2019/1115/od1.html
AAFP

Nov 16th, 2019 - Summary of Recommendation and Evidence The USPSTF recommends that clinicians offer preexposure prophylaxis (PrEP) with effective antiretroviral therapy to persons who are at high risk of HIV acquisition (Table 1). A recommendation.

2019 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; P...
https://www.ahajournals.org/doi/10.1161/CIR.0000000000000734
Circulation Soar J et al

Nov 16th, 2019 - The International Liaison Committee on Resuscitation has initiated a continuous review of new, peer-reviewed, published cardiopulmonary resuscitation science. This is the third annual summary of the International Liaison Committee on Resuscitation International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. It addresses the m...

FDA approves first contact lens indicated to slow the progression of nearsightedness in children
https://www.fda.gov/news-events/press-announcements/fda-approves-first-contact-lens-indicated-slow-progression-nearsightedness-children
FDA

Nov 16th, 2019 - The U.S. Food and Drug Administration today approved the first contact lens indicated to slow the progression of myopia (nearsightedness) in children between the ages of 8 and 12 years old at the initiation of treatment. The MiSight contact lens is a single use, disposable, soft contact lens that is discarded at the end of each day, and is not intended to be worn overnight.

Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association
https://www.ahajournals.org/doi/10.1161/CIR.0000000000000740
Circulation Peter A. Noseworthy, et al.

Nov 14th, 2019 - The widespread use of cardiac implantable electronic devices and wearable monitors has led to the detection of subclinical atrial fibrillation in a substantial proportion of patients. There is evidence that these asymptomatic arrhythmias are associated with increased risk of stroke. Thus, detection of subclinical atrial fibrillation may offer an opportunity to reduce stroke risk by initiating a...

Biggest Threats and Data 2019 AR Threats Report CDC’s Antibiotic Resistance Threats in the United States, 2019
https://www.cdc.gov/drugresistance/biggest-threats.html
CDC

Nov 14th, 2019 - CDC’s Antibiotic Resistance Threats in the United States, 2019 (2019 AR Threats Report) includes the latest national death and infection estimates that underscore the continued threat of antibiotic resistance in the U.S. According to the report, more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. In addition, 223,900...

Diffuse large B cell lymphoma
https://www.cancertherapyadvisor.com/home/decision-support-in-medicine/hematology/diffuse-large-b-cell-lymphoma/
Cancer Therapy Advisor; Thomas M. Habermann

Nov 13th, 2019 - Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma that is potentially curable. DLBCL is the most common non-Hodgkin lymphoma (NHL) representing about 30% of all cases of NHL in the United States of America (USA) and Europe. There are over 76 different types of lymphoma. It is essential to establish the correct histological diagnosis prior to treatment.

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
https://jnccn.org/view/journals/jnccn/17/11/article-p1278.xml
JNCCN Motzer RJ, et al.

Nov 13th, 2019 - The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non–clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-lin...

Marijuana Use Linked to Stroke, Arrhythmia in Young People
https://www.medscape.com/viewarticle/921116
Medscape

Nov 13th, 2019 - Use of marijuana is linked to a higher risk of stroke and hospitalization for cardiac arrhythmia in young people, two new studies suggest.

Diffuse Large B-Cell Lymphoma: ESMO Clinical Practice Guidelines
https://www.esmo.org/Guidelines/Haematological-Malignancies/Diffuse-Large-B-Cell-Lymphoma
Annals of Oncology; Tilly H et al

Nov 13th, 2019 - Diffuse large B-cell lymphoma is relatively common and represents 30%–58% of non-Hodgkin’s lymphomas. The updated ESMO Clinical Practice Guidelines provide information on the current management of diffuse large B-cell lymphoma including recommendations for screening and diagnosis, staging and risk assessment and stage-matched therapeutic strategies including specific recommendations for young a...

2019 AHA/ACC Clinical Performance and Quality Measures for Adults With High Blood Pressure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures
https://www.ahajournals.org/doi/10.1161/HCQ.0000000000000057
Circulation: Cardiovascular Quality and Outcomes; Casey E, et al.

Nov 12th, 2019 - In 2018, the Task Force convened the writing committee to begin the process of revising the existing performance measures set for hypertension that had been released in 2011.3 The writing committee also was charged with the task of developing new measures to evaluate the care of patients in accordance with the 2017 Hypertension Clinical Practice Guidelines.4 The writing committee developed a...

Evidence Mounts for Bariatric Benefit in Obesity-Related Cancer
https://www.medscape.com/viewarticle/921110
Medscape Busko, M

Nov 11th, 2019 - Two studies that provide further support for a potential benefit of a reduced risk of obesity-related cancers post-bariatric surgery were presented here at Obesity Week 2019.

Is There a Difference in Breast Cancer Recurrence Rates After Surgery With Regional vs General Anesthesia?
https://ascopost.com/news/november-2019/is-there-a-difference-in-breast-cancer-recurrence-rates-after-surgery-with-regional-vs-general-anesthesia/
ASCO Post; Stenger M

Nov 11th, 2019 - In a trial reported in The Lancet, Sessler et al found no difference in breast cancer recurrence after surgery with regional anesthesia-analgesia using paravertebral block and propofol vs general anesthesia with the volatile anesthetic sevoflurane and opioid analgesia. They also found no difference in persistent incisional pain between approaches.

Addition of Durvalumab to Etoposide Plus Platinum Chemotherapy for Extensive-Stage SCLC
https://ascopost.com/podcasts/addition-of-durvalumab-to-etoposide-plus-platinum-chemotherapy-for-extensive-stage-sclc/
ASCO Post;

Nov 10th, 2019 - This week, we’ll review an interim analysis of the CASPIAN trial, which evaluated the addition of durvalumab to etoposide plus platinum chemotherapy for extensive-stage small cell lung cancer. Then, we’ll talk about two recently issued guidelines on screening for colorectal cancer. Lastly, we’ll summarize some recent FDA approvals and announcements.

FDA approves first therapy to treat patients with rare blood disorder
https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-treat-patients-rare-blood-disorder
FDA FDA

Nov 9th, 2019 - Today the U.S. Food and Drug Administration granted approval to Reblozyl (luspatercept–aamt) for the treatment of anemia (lack of red blood cells) in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

Top 10 Medical Innovations for 2020, According to Cleveland Clinic
https://www.medscape.com/viewarticle/920936
Medscape

Nov 9th, 2019 - A dual-acting osteoporosis drug, minimally invasive mitral valve surgery, and a new treatment for peanut allergies are among the medical advances that will significantly transform the medical field and improve care for patients in the coming year, according to the Cleveland Clinic's list of top 10 medical innovations for 2020.

Commonly Abused Drugs Charts
https://www.drugabuse.gov/drugs-abuse/commonly-abused-drugs-charts
NIH

Nov 9th, 2019 - Many misused drugs can alter a person’s thinking and judgment, leading to health risks, including addiction, drugged driving and infectious disease. Most drugs could potentially harm an unborn baby; pregnancy-related issues are listed in the chart below for drugs where there is enough scientific evidence to connect the drug use to specific negative effects. Commonly Abused Drugs.

PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets
https://ascopost.com/issues/november-10-2019/prima-trial-reports-benefit-with-niraparib-across-ovarian-cancer-subsets/
ASCO Post; Helwick C

Nov 9th, 2019 - In women with advanced ovarian cancer responding to first-line chemotherapy, maintenance therapy with the PARP inhibitor niraparib significantly reduced the risk of disease progression by 38% overall and by 60% in women with BRCA mutations. Even patients without a homologous recombination deficiency derived advantage from this treatment, in the phase III PRIMA/ENGOT-OV26/GOG-3012 trial presente...

Men With BRCA2 Should Be Screened for Prostate Cancer
https://www.medscape.com/viewarticle/921000
Medscape Davenport L

Nov 7th, 2019 - Men who carry the BRCA2 gene mutation, which is linked to breast and ovarian cancer, are at risk of developing aggressive prostate cancer and so should undergo regular prostate-specific antigen (PSA) testing, suggest findings from a major study.

Diffuse Large B-Cell Lymphoma
https://www.lymphoma.org/aboutlymphoma/nhl/dlbcl/
Lymphoma Research Foundation;

Nov 6th, 2019 - Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States and worldwide, accounting for about 22 percent of newly diagnosed cases of B-cell NHL in the United States. More than 18,000 people are diagnosed with DLBCL each year.

BIOGEN AND ALKERMES ANNOUNCE FDA APPROVAL OF VUMERITY™ (DIROXIMEL FUMARATE) FOR MULTIPLE SCLEROSIS
http://investors.biogen.com/news-releases/news-release-details/biogen-and-alkermes-announce-fda-approval-vumeritytm-diroximel

Nov 5th, 2019 - Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease...

FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older
http://www.news.sanofi.us/2019-11-04-FDA-approves-Fluzone-R-High-Dose-Quadrivalent-Influenza-Vaccine-for-adults-65-years-of-age-and-older

Nov 5th, 2019 - The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for use in adults 65 years of age and older. Fluzone® High-Dose (Influenza Vaccine) was approved by the FDA in 2009 as a trivalent influenza vaccine, including two influenza A strains and one influenza B strain. Fluzone High-Dose Quadri...

Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians
https://annals.org/aim/fullarticle/2754194/screening-colorectal-cancer-asymptomatic-average-risk-adults-guidance-statement-from
Annals of Internal Medicine;

Nov 5th, 2019 - The goal of this American College of Physicians (ACP) guidance statement is to guide clinicians on age to start and stop CRC screening, frequency of screening, and optimal screening test in asymptomatic, average-risk adults, based on a critical review of existing guidelines and their evidence reviews.

FDA authorizes marketing of first next-generation sequencing test for detecting HIV-1 drug resistance mutations
https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-first-next-generation-sequencing-test-detecting-hiv-1-drug-resistance

Nov 5th, 2019 - Today, the U.S. Food and Drug Administration authorized marketing of a test to detect human immunodeficiency virus (HIV) Type-1 drug resistance mutations using next generation sequencing (NGS) technology. The Sentosa SQ HIV Genotyping Assay is the first HIV drug resistance assay that uses NGS technology that the FDA has authorized for marketing in the U.S.

Renin-Angiotensin System Inhibitors vs. Other Antihypertensive Drug Classes for Hypertension
https://www.aafp.org/afp/2019/1101/p540.html
American Family Physician; JEFFREY C. LEGGIT, MD

Nov 5th, 2019 - RAS inhibitors have been widely prescribed to treat hypertension; however, it remains unclear whether they are superior to other antihypertensive drugs in terms of clinically relevant outcomes for primary hypertension.

Millions of Americans have a substance use disorder. Help is available.
https://findtreatment.gov/
SAMHSA

Nov 5th, 2019 - The Substance Abuse and Mental Health Services Administration (SAMHSA) collects information on thousands of state-licensed providers who specialize in treating substance use disorders, addiction, and mental illness.

Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis
https://www.nejm.org/doi/full/10.1056/NEJMoa1909953
The New England Journal of Medicine; Tait, D. et. al.

Oct 28th, 2019 - BACKGROUND Results of an earlier analysis of a trial of the M72/AS01E candidate vaccine against Mycobacterium tuberculosis showed that in infected adults, the vaccine provided 54.0% protection against active pulmonary tuberculosis disease, without evident safety concerns. We now report the results of the 3-year final analysis of efficacy, safety, and immunogenicity. METHODS From August 201...

Scientists design device for oral delivery of injections
https://www.nih.gov/news-events/nih-research-matters/scientists-design-device-oral-delivery-injections

Oct 28th, 2019 - Biologic drugs are complex medications produced from living organisms or their parts. They include vaccines and drugs to treat conditions like rheumatoid arthritis, psoriasis, and cancer. Some biologic drugs, like insulin, can only be delivered by injection. If taken by mouth, stomach acid would destroy the drug before it could take effect.

Risk Factors and Cancer | CDC
https://www.cdc.gov/cancer/risk_factors.htm

Oct 28th, 2019 - Selected risk factors (things that increase your chance of getting cancer), including tobacco and alcohol use and human papillomavirus (HPV).

Shingles - Genetics Home Reference - NIH
https://ghr.nlm.nih.gov/condition/shingles

Oct 28th, 2019 - Shingles (also known as herpes zoster) results from infection by the varicella zoster virus. This common virus causes chickenpox (also known as varicella), which is characterized by itchy spots on the skin that cover the whole body and usually occurs in childhood or adolescence. After the body fights the initial infection, the varicella zoster virus remains in nerve cells for the rest of a per...

Update on Risk of Type III Endoleaks with Use of Endologix AFX Endovascular AAA Graft Systems: FDA Safety Communication
https://www.fda.gov/medical-devices/safety-communications/update-risk-type-iii-endoleaks-use-endologix-afx-endovascular-aaa-graft-systems-fda-safety

Oct 27th, 2019 - The FDA is evaluating new information about the risk of blood continuing to leak into the aneurysm (Type III endoleak) when Endologix AFX endovascular grafts (AFX with Strata, AFX with Duraply, or AFX2) are used for the treatment of abdominal aortic aneurysms (AAA). We’ve previously communicated about the greater risk of Type III endoleaks occurring with the Endologix AFX with Strata device co...

Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial
https://ascopubs.org/doi/abs/10.1200/JCO.19.00693
Journal of Clinical Oncology; Sharma, P. et. al.

Oct 27th, 2019 - PURPOSE To independently validate two biomarkers, a 44-gene DNA damage immune response (DDIR) signature and stromal tumor-infiltrating lymphocytes (sTILs), as prognostic markers in patients with triple-negative breast cancer (TNBC) treated with adjuvant doxorubicin (A) and cyclophosphamide (C) in SWOG 9313. METHODS Four hundred twenty-five centrally determined patient cases with TNBC from ...

Pediatric Metabolic and Bariatric Surgery: Evidence, Barriers, and Best Practices
https://pediatrics.aappublications.org/content/early/2019/10/24/peds.2019-3223
Pediatrics Armstrong, S. et. al.

Oct 27th, 2019 - Severe obesity among youth is an “epidemic within an epidemic” and portends a shortened life expectancy for today’s children compared with those of their parents’ generation. Severe obesity has outpaced less severe forms of childhood obesity in prevalence, and it disproportionately affects adolescents. Emerging evidence has linked severe obesity to the development and progression of multiple co...

Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials
https://jnnp.bmj.com/content/early/2019/08/29/jnnp-2019-320912
Journal of Neurology, Neurosurgery, & Psychiatry; Bai. S., et al

Oct 27th, 2019 - Objectives To systematically review the efficacy and safety of anti-inflammatory agents for patients with major depressive disorders. Methods We searched the literature to identify potentially relevant randomised controlled trials (RCTs) up to 1 January 2019. The primary outcome was efficacy, measured by mean changes in depression score from baseline to endpoint. Secondary outcomes included ...

Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(19)30401-8/fulltext
The Lancet Psychiatry; Black, N. et. al.

Oct 27th, 2019 - Medicinal cannabinoids, including medicinal cannabis and pharmaceutical cannabinoids and their synthetic derivatives, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), have been suggested to have a therapeutic role in certain mental disorders. We analysed the available evidence to ascertain the effectiveness and safety of all types of medicinal cannabinoids in treating symptoms of vario...

Breast Implants - Certain Labeling Recommendations to Improve Patient Communication
https://www.fda.gov/media/131885/download

Oct 23rd, 2019 - This draft guidance contains recommendations concerning the content and format for certain labeling information for saline and silicone gel-filled breast implants. FDA is issuing this draft guidance to help ensure that a patient receives and understands the benefits and risks of these devices. The recommendations are being made based on concerns that some patients are not receiving and/or under...

FDA Approves Botox® (Onabotulinumtoxina) For Pediatric Patients With Lower Limb Spasticity, Excluding Spasticity Caused By Cerebral Palsy
https://www.allergan.com/News/Details/2019/10/FDA%20Approves%20BOTOX%20onabotulinumtoxinA%20for%20Pediatric%20Patients%20with%20Lower%20Limb%20Spasticity%20Excluding%20Sp

Oct 23rd, 2019 - Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application (sBLA) for BOTOX® for the treatment of pediatric patients (2 to 17 years of age) with lower limb spasticity, excluding spasticity caused by cerebral palsy (CP). This marks the 11th BOTOX® therapeutic indication, having been approved for pedi...

Breast Implants: Additional Resources
https://www.fda.gov/medical-devices/breast-implants/breast-implants-additional-resources

Oct 23rd, 2019 - This page suggests other resources for more information on breast implant issues

Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-announces-us-fda-approval-supplemental-new

Oct 23rd, 2019 - Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the U.S. Food and Drug Administration (FDA) has approved BAXDELA® (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by designated susceptible b...

Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32317-7/fulltext

Oct 23rd, 2019 - Uncertainty remains about the optimal monotherapy for hypertension, with current guidelines recommending any primary agent among the first-line drug classes thiazide or thiazide-like diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, dihydropyridine calcium channel blockers, and non-dihydropyridine calcium channel blockers, in the absence of comorbid indications...

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
https://www.nejm.org/doi/full/10.1056/NEJMoa1908075?query=featured_hematology-oncology
The New England Journal of Medicine; Kopetz, S. et. al.

Oct 23rd, 2019 - BACKGROUND Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of pathway reactivation through epidermal growth factor receptor signaling. METHODS In this open-label, phase 3 trial, we enrolled 665 patients with B...

FDA approves niraparib for HRD-positive advanced ovarian cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer

Oct 22nd, 2019 - On October 23, 2019,the Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status. HRD is defined by either a deleterious or suspected deleterious BRCA mu...

Statement on the agency’s continued efforts to protect women’s health and enhance safety information available to patients considering breast implants
https://www.fda.gov/news-events/press-announcements/statement-agencys-continued-efforts-protect-womens-health-and-enhance-safety-information-available

Oct 22nd, 2019 - The U.S. Food and Drug Administration is taking another significant step in protecting women’s health by helping to ensure patients have complete information about the benefits and risks of breast implants. In a draft guidance issued today, we are providing proposed labeling recommendations to manufacturers of these devices to help ensure women receive and understand information regarding the b...

Risks and Complications of Breast Implants
https://www.fda.gov/medical-devices/breast-implants/risks-and-complications-breast-implants

Oct 22nd, 2019 - The webpage provides information about some of the complications and adverse outcomes of breast implants

Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group
https://annals.org/aim/fullarticle/2753604/management-nonvariceal-upper-gastrointestinal-bleeding-guideline-recommendations-from-international-consensus
Annals of Internal Medicine; Barkun, A. et. al.

Oct 21st, 2019 - Description: This update of the 2010 International Consensus Recommendations on the Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding (UGIB) refines previous important statements and presents new clinically relevant recommendations. Methods: An international multidisciplinary group of experts developed the recommendations. Data sources included evidence summarized in ...

FDA, FTC warn company marketing unapproved cannabidiol products with unsubstantiated claims to treat teething and ear pain in infants, autism, ADHD, Parkinson’s and Alzheimer’s disease
https://www.fda.gov/news-events/press-announcements/fda-ftc-warn-company-marketing-unapproved-cannabidiol-products-unsubstantiated-claims-treat-teething

Oct 21st, 2019 - Today, the U.S. Food and Drug Administration and the Federal Trade Commission posted a joint warning letter to Rooted Apothecary LLC, of Naples, Florida, for illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat teething pain and ear aches in infants, autism, attention-deficit/hyperactivity disorder (ADHD), as well as Parki...

FDA approves Fiasp® for use in insulin infusion pumps for adults with type 1 or type 2 diabetes
https://www.novonordisk-us.com/media/news-releases.html?122974

Oct 21st, 2019 - Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has expanded the label for Fiasp® (insulin aspart injection) 100 u/mL to include use in insulin infusion pumps for the improvement of glycemic control in adults with type 1 or type 2 diabetes.1 Fiasp®, a rapid-acting insulin, was approved by the FDA in 2017 for use by intravenous infusion under supervision by a health...

2019 Supportive Care: Anxiety, Depression, and Low Social Support Are Significant Factors in Cancer Pain Intensity
https://ascopost.com/news/october-2019/anxiety-depression-and-low-social-support-are-significant-factors-in-cancer-pain-intensity/

Oct 21st, 2019 - Pain is one of the most common symptoms associated with cancer and its treatment, and feelings of anxiety and depression can intensify the level of pain patients experience, according to the results from a study by Galloway et al that will be presented at the 2019 Supportive Care in Oncology Symposium (Abstract 76). However, authors also reported that having greater social support can help miti...

Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection
https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-us-fda-approval-biorphenr

Oct 21st, 2019 - Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that the U.S. Food and Drug Administration (FDA) has approved Biorphen®, the first and only FDA-approved ready-to-use formulation of phenylephrine for the treatment of clinically important hypotension resulting primarily from vasodilat...

Relief and Prevention of Congestion in Heart Failure Enhance Quality and Length of Life
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.042660
Circulation Drazner, M. et. al.

Oct 20th, 2019 - This article is a commentary on the following Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction

Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
https://www.prnewswire.com/news-releases/janssen-announces-us-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis-300941913.html

Oct 20th, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration's (FDA) approval of STELARA® (ustekinumab) for the treatment of adult patients with moderately to severely active ulcerative colitis. The approval for this new indication is based on the pivotal Phase 3 UNIFI clinical trial which achieved its primary endpoint of clinical remission. Re...

Farxiga approved in the US to reduce the risk of hospitalisation for heart failure in patients with type-2 diabetes
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2019/farxiga-approved-in-the-us-to-reduce-the-risk-of-hospitalisation-for-heart-failure-in-patients-with-type-2-diabetes-21102019.html

Oct 20th, 2019 - AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.

FDA approves new breakthrough therapy for cystic fibrosis
https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis

Oct 20th, 2019 - The U.S. Food and Drug Administration today approved Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation. Trikafta is approved for patients 12 years and older with cystic fibrosis who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, wh...

Pan-viral serology implicates enteroviruses in acute flaccid myelitis
https://www.nature.com/articles/s41591-019-0613-1
Nature Medicine; Schubert, R. et. al.

Oct 20th, 2019 - Since 2012, the United States of America has experienced a biennial spike in pediatric acute flaccid myelitis (AFM)1,2,3,4,5,6. Epidemiologic evidence suggests non-polio enteroviruses (EVs) are a potential etiology, yet EV RNA is rarely detected in cerebrospinal fluid (CSF)2. CSF from children with AFM (n = 42) and other pediatric neurologic disease controls (n = 58) were investigated for intra...

Metoprolol for the Prevention of Acute Exacerbations of COPD
https://www.nejm.org/doi/full/10.1056/NEJMoa1908142
The New England Journal of Medicine; Dransfield, M. et. al.

Oct 19th, 2019 - Observational studies suggest that beta-blockers may reduce the risk of exacerbations and death in patients with moderate or severe chronic obstructive pulmonary disease (COPD), but these findings have not been confirmed in randomized trials.

TCT 2019: Top Interventional Takeaways
https://www.acc.org/latest-in-cardiology/articles/2019/10/06/24/42/tct-2019-top-interventional-takeaways

Oct 17th, 2019 - TCT 2019 in San Francisco has left us with a few trials that potentially may change our interventional practice. The COMPLETE study is now complete! To refresh your memory, the COMPLETE trial was presented at ESC Congress 2019, one month before TCT, and studied patients presented with STEMI and multivessel disease. At a median of three-years follow-up, complete revascularization was superior to...

Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers
https://www.foamix.com/news-releases/news-release-details/update-foamix-receives-fda-approval-amzeeqtm-topical-minocycline

Oct 17th, 2019 - Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved its novel AMZEEQTM (minocycline) topical foam, 4%. AMZEEQ, formerly known as FMX101, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric...

Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications
https://www.gene.com/media/press-releases/14817/2019-10-17/genentech-announces-fda-approval-of-xofl

Oct 16th, 2019 - Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control and Prevention (CDC) defines people at high risk of serious flu complications as those who have conditions such as asthma, chronic lung disease, diabetes, heart disease, morbid obesity or adults ...

Pathological personality facets and emotion (dys)regulation in gambling disorder
https://onlinelibrary.wiley.com/doi/abs/10.1111/sjop.12579
Scandinavian Journal of Psychology; Roiger, G. et. al.

Oct 16th, 2019 - A number of researches showed high prevalence of personality disorders among addicted gamblers. However, there are still few studies investigating the role of pathological personality facets in Gambling Disorder (GD). Moreover, the nature of the relationship between GD and pathological personality is not clear. We administered to a group of addicted gamblers (N = 79) and a group of healthy part...

Weight change across adulthood in relation to all cause and cause specific mortality: prospective cohort study
https://www.bmj.com/content/367/bmj.l5584
BMJ Chen, C. et. al.

Oct 15th, 2019 - Objective To investigate the association between weight changes across adulthood and mortality. Design Prospective cohort study. Setting US National Health and Nutrition Examination Survey (NHANES) 1988-94 and 1999-2014. Participants 36 051 people aged 40 years or over with measured body weight and height at baseline and recalled weight at young adulthood (25 years old) and middle adul...

Association of Cardiovascular Disease With Premature Mortality in the United States
https://jamanetwork.com/journals/jamacardiology/fullarticle/2752889
JAMA Cardiology; Chen, Y. et. al.

Oct 15th, 2019 - Question How have the trends in premature mortality from cardiovascular disease (CVD) changed in the United States during 2000 to 2015 by demographics and county-level factors, including education, rurality, and the prevalence of smoking, obesity, and diabetes? Findings In this study, CVD mortality rates increased significantly among American Indian/Alaska Native individuals age 25 to 49 y...

Statins for primary prevention of cardiovascular disease
https://www.bmj.com/content/367/bmj.l5674/article-info
BMJ Byrne, P. et. al.

Oct 15th, 2019 - Statins are now the most commonly used drug in the UK and one of the most commonly used medicines in the world.12 Although prices have fallen since their patents expired, statins account for substantial drug expenditure in a context of often overstretched healthcare budgets, with estimated global sales approaching $1tn by 2020.3 Use of statins in people with established cardiovascular disease i...

U.S. FDA Approves SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia
http://www.noven.com/PR101519.php

Oct 14th, 2019 - Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced the U.S. Food and Drug Administration (FDA) has approved SECUADO® (asenapine) transdermal system, the first-and-only transdermal patch formulation for the treatment of adults with schizophrenia.1 “As people living with schizophrenia cycle through treatments their therapeutic options ...

Philips introduces new 200mm and 150mm Stellarex 0.035” low-dose drug-coated balloons to broaden treatment options for peripheral artery disease patients
https://www.philips.com/a-w/about/news/archive/standard/news/press/2019/20191015-philips-introduces-new-200mm-and-150mm-stellarex-035-low-dose-drug-coated-balloons.html

Oct 14th, 2019 - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced two new balloons to its Stellarex 0.035” low-dose drug-coated balloon (DCB) portfolio. The new 200mm and 150mm Stellarex 0.035” low-dose DCBs have received approval from the U.S. Food and Drug Administration (FDA) for the treatment of de novo and restenotic lesions in native superficial femoral or popli...

Predicting the Risk of Postoperative Pulmonary Complications
https://www.aafp.org/afp/2019/1015/p499.html
American Family Physician;

Oct 14th, 2019 - The incidence of pulmonary complications following major surgery is estimated to be 1% to 23%, with the risk varying based on patient factors and the type of surgery.1 Postoperative pulmonary complications include pneumonia, tracheobronchitis, pulmonary edema, pulmonary embolism, atelectasis, pleural effusion, pneumothorax, bronchospasm, aspiration, respiratory failure, and acute respiratory di...

Influenza Vaccination: Updated Recommendations from ACIP
https://www.aafp.org/afp/2019/1015/p505.html

Oct 14th, 2019 - The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) has released its recommendations for routine influenza vaccination in the 2019–2020 season. Updates this year include the antigenic composition of seasonal influenza vaccines available in the United States and changes related to recent regulatory actions, including labeling changes for previousl...

Nail Changes Following a Viral Infection: Photo Quiz
https://www.aafp.org/afp/2019/1015/p497.html
American Family Physician;

Oct 14th, 2019 - A seven-year-old boy presented with abnormal growth of his fingernails that began two weeks prior. He had no other symptoms, including pain or pruritus on his hands or around his nails. He did not have fevers, chills, nausea, vomiting, or change in activity. He had hand-foot-and-mouth disease two months earlier that was diagnosed based on vesicular lesions in his mouth and on his hands and feet...

Acne Vulgaris: Diagnosis and Treatment
https://www.aafp.org/afp/2019/1015/p475.html
American Family Physician;

Oct 14th, 2019 - Acne vulgaris is the most prevalent chronic skin disease in the United States, affecting nearly 50 million people per year, mostly adolescents and young adults. Potential sequelae of acne, such as scarring, dyspigmentation, and low self-esteem, may result in significant morbidity. Typical acne lesions involve the pilosebaceous follicles and the interrelated processes of sebum production, Cutiba...

ASCO Breakthrough: Breast Cancer Gene Expression Signature May Help Predict Recurrence Postradiotherapy
https://ascopost.com/news/october-2019/breast-cancer-gene-expression-signature-may-help-to-predict-recurrence-postradiotherapy/

Oct 13th, 2019 - Researchers have identified a gene pattern that may help predict which patients with breast cancer will have early or late disease recurrence following radiation therapy. The ability to predict the timing of recurrence could change—and improve—treatment strategies and determine the length of follow-up needed. These findings were presented by Speers et al at ASCO Breakthrough: A Global Summit fo...

The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: New features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed...
https://academic.oup.com/eurheartj/article/40/39/3215/5586545
European Heart Journal; Grant, P. et. al.

Oct 13th, 2019 - The prevalence of diabetes continues to increase, with 60 million thought to have diabetes in Europe in 2017 and predictions of more than 600 million individuals with diabetes worldwide by 2045. These numbers carry a huge burden of morbidity and mortality with a high prevalence of microvascular disease affecting the eyes, nerves, and kidneys and macrovascular disease leading to CV, cerebrovascu...

U.S. FDA Approves XARELTO® (rivaroxaban) to Help Prevent Blood Clots in Acutely Ill Medical Patients
https://www.jnj.com/u-s-fda-approves-xarelto-rivaroxaban-to-help-prevent-blood-clots-in-acutely-ill-medical-patients

Oct 13th, 2019 - he Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban) for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding. With the approval of this new indication, XAREL...

Do High-Dose Statins Increase the Risk for Osteoporosis?
https://www.medscape.com/viewarticle/919825

Oct 13th, 2019 - The protective effect of statin therapy on bone health that has been demonstrated in some studies may be dose-related, and although low doses are associated with a reduced risk for osteoporosis, high doses were linked to an increased risk of the bone disease in new research.

FDA approves new treatment for patients with migraine
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-patients-migraine

Oct 10th, 2019 - The U.S. Food and Drug Administration today approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Reyvow is not indicated for the preventive treatment of migraine.

Smoking & Tobacco Use For Healthcare Providers
https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease/healthcare-providers/index.html

Oct 10th, 2019 - CDC investigates outbreak of severe lung disease in patients who have recently used e-cigarette products, also known as “vaping.

Esophageal Cancer Treatment (Adult) (PDQ®)–Health Professional Version
https://www.cancer.gov/types/esophageal/hp/adult/esophageal-treatment-pdq

Oct 10th, 2019 - Two histologic types account for the majority of malignant esophageal neoplasms: adenocarcinoma and squamous cell carcinoma. Adenocarcinomas typically start in the lower esophagus and squamous cell carcinoma can develop throughout the esophagus. The epidemiology of these types varies markedly.

Gastric Cancer Treatment (PDQ®)–Health Professional Version Go to Patient Version
https://www.cancer.gov/types/stomach/hp/stomach-treatment-pdq

Oct 10th, 2019 - Gastric cancer treatment options depend on extent of disease and may include radical surgery, chemotherapy, radiation, and immunotherapy. Get detailed information about the diagnosis, treatment, and prognosis of newly diagnosed and recurrent gastric cancer in this clinician summary.

Early pharmacological interventions for preventing post‐traumatic stress disorder (PTSD): a network meta‐analysis
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013443/full
The Cochrane Database of Systematic Reviews;

Oct 9th, 2019 - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the efficacy and acceptability of pharmacological interventions for preventing post‐traumatic stress disorder (PTSD) in adults exposed to a traumatic event and to generate a clinically useful ranking of pharmacological interventions according to their efficacy and acceptability by performing a n...

Following NCCN Guidelines for Metastatic Breast Cancer Results in Lower Costs for Patients, According to New Study
https://www.nccn.org/about/news/newsinfo.aspx?NewsID=1712

Oct 9th, 2019 - A new study from the O’Neal Comprehensive Cancer Center at University of Alabama at Birmingham (UAB), published in the October 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network, finds that direct costs for metastatic breast cancer (MBC) patients increase dramatically when their treatment differs from recommendations in the NCCN Clinical Practice Guidelines in Oncology (N...

Researchers Identify Genetic Markers for Response to Radiation Therapy and Prediction of Recurrence
https://www.asco.org/about-asco/press-center/news-releases/researchers-identify-genetic-markers-response-radiation

Oct 9th, 2019 - Genetic information could help identify patients likely to respond to radiation therapy and predict when disease recurrence following radiation is likely to occur. This could help clinicians better tailor treatment strategies to individual patients to boost efficacy, while minimizing unwanted side effects. The findings come from two studies that will be presented at ASCO Breakthrough: A Global ...

Coverage from the International Congress of Parkinson’s Disease and Movement Disorders (MDS) 2019
https://www.medscape.com/viewcollection/35073

Oct 8th, 2019 - International Congress of Parkinson’s Disease and Movement Disorders (MDS) 2019: Read clinically focused news coverage of key developments from MDS 2019

Recent Trends in the Treatment and Prognosis of Male Breast Cancer
https://ascopost.com/news/october-2019/recent-trends-in-the-treatment-and-prognosis-of-male-breast-cancer/

Oct 8th, 2019 - A recent analysis published by Yadav et al in Cancer reviewed how the treatment of male breast cancer has evolved over the years 2004 to 2014. In addition, certain patient-, tumor-, and treatment-related factors were found to be linked with better survival.

Longitudinal Associations Between Income Changes and Incident Cardiovascular Disease
https://jamanetwork.com/journals/jamacardiology/article-abstract/2752544
JAMA Cardiology; Wang, S. et. al.

Oct 8th, 2019 - Question What is the association between bidirectional income change and cardiovascular disease? Findings In this cohort study of middle-aged, community-dwelling adults, a more than 50% income drop was significantly associated with higher risk of incident cardiovascular disease, while a more than 50% income rise was significantly associated with lower risk of incident cardiovascular diseas...

FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-increase-pain-free-light-exposure-patients-rare-disorder

Oct 7th, 2019 - The U.S. Food and Drug Administration today granted approval to Scenesse (afamelanotide) to increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria.

Dog Ownership and Survival
https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.119.005554
Circulation Kramer, C. et. al.

Oct 7th, 2019 - Dog ownership has been associated with decreased cardiovascular risk. Recent reports have suggested an association of dog companionship with lower blood pressure levels, improved lipid profile, and diminished sympathetic responses to stress. However, it is unclear if dog ownership is associated with improved survival as previous studies have yielded inconsistent results. Thus, we performed a sy...

ESMO 2019: Overall Survival With Immunotherapy Doublet vs Chemotherapy in Advanced NSCLC
https://ascopost.com/news/october-2019/overall-survival-with-nivolumabipilimumab-vs-chemotherapy-in-advanced-nsclc/

Oct 7th, 2019 - As reported at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract LBA4) and simultaneously in The New England Journal of Medicine by Matthew D. Hellmann, MD, and colleagues, the phase III CheckMate 227 trial has shown that nivolumab plus ipilimumab improved overall survival vs chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) with programmed cell de...

Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept

Oct 7th, 2019 - Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Beovu® (brolucizumab) injection, also known as RTH258 for the treatment of wet age-related macular degeneration (AMD)[1]. Beovu is the first FDA approved anti-VEGF to offer both greater fluid resolution versus aflibercept and the ability to maintain eligible wet AMD patients on a three-month dosing interval immed...

A Clinician's Guide to Healthy Eating for Cardiovascular Disease Prevention
https://www.acc.org/latest-in-cardiology/articles/2019/10/08/13/20/a-clinicians-guide-to-healthy-eating-for-cvd-prevention

Oct 7th, 2019 - The recently released 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease has given clinicians a comprehensive, evidence-based resource to inform management of patients at increased risk of atherosclerotic cardiovascular disease. In addition to guidance on risk stratification and medication prescribing, the Prevention Guideline stresses the importance of lifestyle interve...

Three Leading National Public Health Organizations Ring The Alarm About All-time Highs Of STDs
http://www.ncsddc.org/three-leading-national-public-health-organizations-ring-the-alarm-about-all-time-highs-of-stds/

Oct 7th, 2019 - Data released this week by the Centers for Disease Control and Prevention (CDC) show STDs have surged for the fifth consecutive year, reaching an all-time high in the U.S. These dangerous trends in chlamydia, gonorrhea, and syphilis show no sign of slowing and affect millions of lives each year in the United States. Particularly worrisome is the emerging trend of newborn syphilis (congenital sy...

Statin Use in Primary Prevention of ASCVD According to 5 Guidelines
https://www.acc.org/latest-in-cardiology/journal-scans/2019/10/08/11/49/statin-use-in-primary-prevention-of-atherosclerotic

Oct 7th, 2019 - Is there a difference in the sensitivity, specificity, and estimated number needed to treat (NNT10) with a statin to prevent one atherosclerotic cardiovascular disease (ASCVD) event in 10 years by criteria from five of the major guidelines?

Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease - AMBER
https://www.acc.org/latest-in-cardiology/clinical-trials/2019/10/08/14/26/amber

Oct 7th, 2019 - The AMBER trial showed that the potassium binder patiromer was effective at allowing more patients to remain on spironolactone.

California OKs pharmacists to dispense HIV prevention meds
https://apnews.com/a1491134e0c242bc95ef36ed0a9fa95e

Oct 6th, 2019 - Pharmacists in California will be able to dispense HIV prevention pills to patients without a doctor’s prescription after Gov. Gavin Newsom signed legislation Monday that supporters say will greatly reduce the spread of infection. Advocates of Senate Bill 159 say California is the first state to authorize pre-exposure prophylaxis, also called PrEP, and post-exposure prophylaxis, known as PEP...

Optimizing Postprandial Glucose Management in Adults With Insulin-Requiring Diabetes: Report and Recommendations
https://academic.oup.com/jes/article/3/10/1942/5581189
Journal of the Endocrine Society;

Oct 6th, 2019 - Faster-acting insulins, new noninsulin drug classes, more flexible insulin-delivery systems, and improved continuous glucose monitoring devices offer unprecedented opportunities to improve postprandial glucose (PPG) management and overall care for adults with insulin-treated diabetes. These developments led the Endocrine Society to convene a working panel of diabetes experts in December 2018 to...

Cannabis and cannabinoids for people with multiple sclerosis
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013444/full

Oct 6th, 2019 - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess benefit and safety of cannabis‐based medicines, including synthetic, or herbal and plant‐derived cannabinoids, for people with MS.